MARKET

VRPX

VRPX

Virpax Pharmaceuticals Inc
NASDAQ
4.260
+0.490
+13.00%
Opening 15:01 03/28 EDT
OPEN
3.720
PREV CLOSE
3.770
HIGH
4.260
LOW
3.720
VOLUME
13.66K
TURNOVER
0
52 WEEK HIGH
11.77
52 WEEK LOW
2.402
MARKET CAP
4.99M
P/E (TTM)
-0.3665
1D
5D
1M
3M
1Y
5Y
Virpax Pharmaceuticals’ Settlement Strain: Risk of Stalled Development and Hindered Growth
TipRanks · 1d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Apollomics (NASDAQ:APLM) stock rose 10.9% to $0.61 during Tuesday's after-market session. The company's, Q4 earnings came out today. Cara Therapeutics shares moved upwards by 7.36% and Iridex stock increased by 5.52%. Losers Akili and Mira Pharmaceuticals were the biggest losers in the market.
Benzinga · 1d ago
Virpax Pharmaceuticals GAAP EPS of -$12.97 misses by $4.77
Virpax Pharmaceuticals GAAP EPS of -$12.97 misses by $4.77. As of December 31, 2023, Virpax had cash of approximately $9.1 million. The company expects to close out the year with a positive cash balance.
Seeking Alpha · 2d ago
*Virpax Pharmaceuticals 2023 Operating Loss $15.2M>VRPX
Dow Jones · 2d ago
Press Release: Virpax Pharmaceuticals Reports 2023 Year-End Results
Virpax Pharmaceuticals, Inc. Reports financial results for the twelve months ended December 31, 2023. The company is developing non-addictive products for pain management, post-traumatic stress disorder, and viral barrier indications. Virpax is on track to file the IND for Envelta(TM) later in 2024.
Dow Jones · 2d ago
Press Release: Virpax Pharmaceuticals Reports -2-
Company's ability to successfully complete research and further development, and commercialization of Company drug candidates. The Company faces a number of risks and uncertainties. The Company's forward-looking statements speak only as of the date of this press release. The company has no obligation to update such statements.
Dow Jones · 2d ago
*Virpax Pharmaceuticals Strong Start tp 2024 >VRPX
Dow Jones · 2d ago
Weekly Report: what happened at VRPX last week (0318-0322)?
Weekly Report · 3d ago
More
About VRPX
Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and drug delivery systems. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, PES200, AnQlar and NobrXiol. Probudur is a drug product candidate based on a liposomal delivery system utilizing large multi-vesicular vesicles (LMVVs) encapsulating a high dose of the local anesthetic bupivacaine. PES200 enables the delivery of a metabolically labile peptide drug (Enkephalin) into the brain for post-traumatic stress disorder. NobrXiol is being developed by Nanomerics as an investigational formulation delivered via the nasal route to enhance Cannabidiol transport to the brain.

Webull offers Virpax Pharmaceuticals Inc stock information, including NASDAQ: VRPX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRPX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRPX stock methods without spending real money on the virtual paper trading platform.